Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 Favorable and differentiated ...

Phenomenex Introduces Biozen™ Native RP-1 and RP-5: A Novel Way to Characterize ADCs with Unmatched Throughput and High-Quality Data Published 9:01 am Tuesday, March 25, 2025 ...

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials ...